CurrentCignaPolicy IP0757

Drug Coverage Policy - Treprostinil Injection

Defines prior authorization and coverage criteria for treprostinil injection (Remodulin and generic) for pulmonary arterial hypertension (WHO Group 1) and supportive use in chronic thromboembolic pulmonary hypertension (CTEPH). Includes documentation, prescriber specialty, and product-preference rules for employer/IFP plans.

Policy Summary

PayerCigna

PolicyDrug Coverage Policy - Treprostinil Injection

Policy CodePolicy IP0757

Change TypeNew policyinitial therapy revisions

Effective DateDec 1, 2025

Next Review Date

Key ActionPrior Authorization is required for treprostinil injection; approvals are generally for 1 year, or up to 14 days when criteria are not met or information is insufficient; all short-term approvals reviewed by a nurse or pharmacist.

SourceLink

POLICY UPDATE CHANGES

New policy created (Summary of Changes = New policy).

Selected revision referencing initial therapy and specific products (Orenitram, Uptravi) noted under PAH initial therapy.

1Primary FDA Indication (PAH WHO Group 1)

1Supportive Evidence Indication (CTEPH)

J3285Covered HCPCS code

14Short-term approval days when criteria unmet

Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.

Coverage Summary

Coverage stance: covered_with_criteria. Scope: Defines prior authorization and coverage criteria for treprostinil injection (Remodulin and generic) for pulmonary arterial hypertension (WHO Group 1) and supportive use in chronic thromboembolic pulmonary hypertension (CTEPH). Subject: Treprostinil Injection (Remodulin) coverage. Status: CURRENT. Effective date: 2025-12-01. Last review: 2025-11-15.

Initial Therapy Criteria (FDA Indication - PAH WHO Group 1)

FDA-Approved Indication - Pulmonary Arterial Hypertension (PAH) WHO Group 1

Approve for 1 year if the patient meets ONE of the following (A or B):

ref

Continuation Therapy Criteria

FDA-Approved Indication - Pulmonary Arterial Hypertension (PAH) WHO Group 1

Approve for 1 year if the patient meets ONE of the following (A or B):

ref

Billing Rule

Approval duration and review

Approvals are provided for 1 year unless otherwise noted. Cases not meeting policy criteria or with insufficient information may receive a short-term approval of up to 14 days. All short-term approvals are reviewed by a nurse or pharmacist.

Approvals generally for 1 year
Short-term approvals up to 14 days when criteria not met or information insufficient
Short-term approvals reviewed by a nurse or pharmacist

Other Uses with Supportive Evidence (CTEPH)

Other Uses with Supportive Evidence

Approve for 1 year if prescribed by or in consultation with a pulmonologist or cardiologist:

ref

Guidance and evidence supporting use include the CHEST guideline update (2019) and the ESC/ERS guidelines (2022). Prescribing information cited includes United Therapeutics Remodulin (October 2023) and Sandoz treprostinil prescribing information (April 2023).

Employer & Individual/Family Plans — Remodulin Product Rules

Employer Plans and Individual and Family Plans - Remodulin product-specific criteria

Remodulin coverage criteria for Employer and Individual/Family Plans:

ref

Documentation Required

Employer/IFP Remodulin substitution rules

For Employer and Individual/Family Plans requesting Remodulin, the member must have tried generic treprostinil or document inability to use generic treprostinil due to lack of compatible durable medical equipment (e.g., no compatible pump to administer generic product).

Must try generic treprostinil first (Employer/IFP)
Or document inability to use generic due to lack of compatible DME (e.g., compatible pump)

Exclusions / Not Medically Necessary

Treprostinil injection is considered not medically necessary for any use not meeting policy criteria, including but not limited to:

ref

Denial Risk

Requests not meeting criteria may be denied

Requests that do not meet the policy criteria are considered not medically necessary and may be denied. Examples include use for indications outside WHO Group 1 PAH and concurrent use with parenteral epoprostenol, oral prostacyclin products, or inhaled prostacyclin agents; prior authorization is required and lack of required documentation may lead to denial.

Not medically necessary when used for conditions not meeting policy (e.g., COPD without PAH)
Concurrent use with other prostacyclin products is excluded
Prior authorization required; missing documentation or unmet criteria may result in denial

Applicable Codes

Covered HCPCS - Treprostinil injectionHCPCSCovered

J3285

Injection, treprostinil, 1 mg

Provider Actions & Requirements

Prior Authorization

Prior authorization required

Prior authorization is required for treprostinil injection (HCPCS J3285). Approvals are generally for 1 year; if criteria are not met or information is insufficient, a short-term approval up to 14 days may be granted (all short-term approvals are reviewed by a nurse or pharmacist).

Prior authorization required
J3285 (Injection, treprostinil, 1 mg)
Approvals generally for 1 year; short-term up to 14 days when criteria not met

Documentation Required

Right heart catheterization documentation

Provide documentation of right heart catheterization and the catheterization results confirming WHO Group 1 PAH as part of initiation and many continuation approvals. Acceptable documentation includes chart notes and catheterization laboratory results. If these documents were previously provided for another PAH medication's prior authorization, that prior provision satisfies this requirement.

Right heart catheterization documentation required to confirm WHO Group 1 PAH

Clinical Evidence & Guidelines

Key evidence sources: guidelines — CHEST 2019 and ESC/ERS 2022; prescribing information — United Therapeutics Remodulin, Oct 2023 and Sandoz, Apr 2023.

Background

Treprostinil is a prostacyclin vasodilator indicated for pulmonary arterial hypertension (PAH, WHO Group 1) to diminish exercise-related symptoms and reduce clinical deterioration. It has been used in CTEPH with variable results. Diagnosis of PAH requires confirmation by right heart catheterization.

Revision History

2025-11-15policy_creationLatest

New policy created (Summary of Changes = New policy).

2025-12-01effective_dateLatest

Policy effective date established.

2025-11-15revision